Autologous, hapten-modified vaccine as a treatment for human cancers

Seminars in Oncology

Volumn 25, Issue 6, 1998, Pages 646-653

  Berd, D ^a   Kairys, J ^a   Dunton, C ^a   Mastrangelo, M J ^a   Sato, T ^a   Maguire H C , Jr ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; T LYMPHOCYTE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HUMAN; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS; DINITROBENZENES; FEMALE; HAPTENS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ACTIVE; INFLAMMATION; LUNG NEOPLASMS; MALE; MELANOMA; MYCOBACTERIUM BOVIS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0031649505     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)